Coronary Artery Disease
Conditions
Keywords
Myocardial Blood Flow (MBF), Myocardial Perfusion Imaging (MPI), RAPID-WATER-FLOW, Positron Emission Tomography (PET), Oxygen-15, Coronary Artery Disease (CAD)
Brief summary
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine). A safety follow-up phone call will occur 24 ± 8 hrs after completion of the \[15-O\]-H2O scan.
Interventions
DRUG[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
Sponsors
MedTrace Pharma A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study. All participants will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male and female participants ≥18 years; 2. Informed consent form (ICF) read, signed, and dated prior to any study procedures being performed; 3. Participants who fall into any one of the following categories: 1. Have been referred for an ICA directly of after non-invasive testing (e.g., SPECT or PET MPI, stress echo, CCTA, ETT). 2. Had an ICA with no intervention. However, if any stenosis \>40% but ≤70% was observed, an FFR or iFR assessment was performed. 3. Had a CCTA with normal coronaries or minimal CAD (no stenosis \>25%). The SPECT study, PET 15O-H2O study, and ICA or CCTA testing need to be completed within a 30-day window, with time 0 defined as the date of the first of these three tests. 4. Women of Child Bearing Potential (WOCBP) must be non-pregnant, and non-lactating. For women of childbearing potential, the results of a urine human chorionic gonadotropin (HCG) pregnancy test (with the result known on the day of drug administration) must be negative; these participants must be practicing appropriate birth control from time of the screening visit until the end of the follow-up period. For women who are either surgically sterile (have a documented bilateral tubal ligation or oophorectomy and/or hysterectomy) or are post-menopausal (cessation of menses for more than 1 year), enrollment in the study without a pregnancy test at screening is allowed. 5. Male will need to use contraceptive methods until end of the follow-up period. 6. Participants are able to comply with all study procedures as described in the protocol.
Exclusion criteria
1. Participants are unable to undergo (even partially) any of the imaging procedures; 2. Participants with a known history of cardiac disease including: 1. myocardial infarction, previous coronary revascularization, or chronic ischemic cardiomyopathy 2. primary myocardial disease such as cardiac amyloidosis or hypertrophic cardiomyopathy 3. known left ventricular dysfunction 4. moderate or severe aortic or mitral stenosis or regurgitation 3. Participants in whom adenosine stress testing is contraindicated, including but not limited to: 1. Participants with severe COPD or chronic asthma. 2. Participants with second- or third-degree atrioventricular block without a pacemaker. 4. Participants with claustrophobia to an extent that would limit their ability to undergo SPECT and PET imaging (patients whose claustrophobia is known to be readily controlled with drugs or psychological support may be enrolled). 5. Participants who are on sildenafil (Viagra) or oral dipyridamole (Persantine, Aggrenox) therapy or on any PDE5 inhibitor (i.e. tadalafil, avanafil, vardenafil),and for whom its use cannot be terminated or suspended for ≥24 hours prior to treatment of study drug. 6. Participants with significant co-morbidities that would prevent appropriate completion of the protocol procedures. 7. Participants who have participated in another research study using investigational drugs within the 30 days prior to enrollment or through the duration of the trial (patients in observational studies with approved agents and participants known to be on placebo may be enrolled). 8. Participants who have previously participated in this study. 9. Subjects scheduled for, or planning to undergo, any interventional cardiac procedures between enrollment and ICA (pathway 1) or signing of informed consent and 15O-H2O PET MPI (pathway 2 and 3)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and specificity of the [15-O]-H2O PET study using the truth-standard of ICA with FFR/iFR or CCTA. | 30 days | Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity, specificity, and accuracy of [15-O]-H2O PET MPI in participants of special clinical interest (female, BMI≥30, diabetics, multivessel disease). | 30 days | Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP) * Accuracy: (TN + TP)/(TN + TP + FN + FP) |
| Sensitivity and specificity of 15O-H2O PET in subjects where the standard of truth may use site-determined value of FFR/iFR when the raw FFR/iFR data are not available to the core lab. | 30 days | Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP) * Accuracy: (TN + TP)/(TN + TP + FN + FP) |
| Adverse event analyses will include tabulations of the incidence (number and percent of subjects) with at least one TEAEs overall and by MedDRA system organ class (SOC) and preferred term (PT). This will be repeated for serious adverse. | 30 days | Other Safety measures including the following will be summarized descriptively: 1. ECG (ventricular heart rate, PR interval, QRS duration, QT interval, QTc interval) 2. Vital Signs 3. Concomitant Medications 4. Protocol Deviations |
Countries
Canada, Denmark, Germany, Netherlands, Sweden, United States
Contacts
STUDY_DIRECTORNicholas Borys, MD
MedTrace Pharma A/S
PRINCIPAL_INVESTIGATORMarcelo DiCarli, MD
Brigham and Women's Hospital
Outcome results
None listed